Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 16, 2005 Jack Uldrich	What Drives Accelrys? Is the scientific software company revving up, slowing down, or stuck in neutral? If you want to invest, tread carefully; limit orders are always a good idea in micro-cap land.
Bio-IT World March 8, 2005 Salvatore Salamone	Nano Poised for Liftoff First 'nano' technologies yield fruit in the biomedical lab and clinic with the promise of more to come.
The Motley Fool November 16, 2005 Jack Uldrich	The Next Big Little Market Accelrys' efforts to position itself at the crossroads of nanotech and biotech, and help facilitate new discoveries in those fields through informatics software, could reap considerable rewards for the company and its shareholders.
The Motley Fool September 12, 2005 Jack Uldrich	Nanotech's Promise Hits the Pedal The news that certain major chemical companies have climbed onboard offers additional support to Accelrys' claims that the consortium is creating software tools to speed up the design of new nanomaterials and devices. Investors, take note.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
Chemistry World April 11, 2006 Jon Evans	Nanotechnology Tackles Chemotherapy Chemists and medical researchers have developed nanoparticles that target chemotherapy drugs directly at tumours. The researchers claim that the same technique could be used to develop nanoparticle-based treatments for a wide range of other diseases.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool January 16, 2009 Brian Orelli	Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
Chemistry World January 24, 2014 Megan Tyler	Nanomaterials: Bin and burn? Scientists in the US have begun addressing the question of whether the disposal of nanomaterials could damage the environment, by investigating the fate of nanomaterials in incinerators.
The Motley Fool March 2, 2004 Wherrett & Yelovich	Commercializing Nanotechnology This article gives you an overview of the three "industries" -- nanomaterials, nanobiotechnology, and nanoelectronics -- that will most use the technology, and some of the companies poised to benefit from the emerging science.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool January 23, 2004 Alyce Lomax	Amgen's Engine Is the drug company geared up for success?
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
The Motley Fool December 28, 2005 Stephen D. Simpson	AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either.
Chemistry World March 27, 2013 Eugene Gerden	Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool February 2, 2007	No Acceleration at Accelrys: Fool by Numbers The medical and nanotech software specialist released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
Chemistry World August 3, 2010 Lewis Brindley	Nanoparticles and ultrasound team up to treat tumors A new, non-invasive method to deliver drugs to the brain has been developed by Taiwanese researchers.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
ifeminists December 28, 2005 Tony Zizza	If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs.
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
Chemistry World February 14, 2014 Jason Woolford	Sandy nanoparticles for safer-by-design sunscreens Nanoparticles coated with an inert layer of silica could be used in sunscreens and cosmetics to reduce the potential hazards of these increasingly indispensable materials, new research shows.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?